243 related articles for article (PubMed ID: 16122284)
1. Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants.
Puozzo C; Lens S; Reh C; Michaelis K; Rosillon D; Deroubaix X; Deprez D
Clin Pharmacokinet; 2005; 44(9):977-88. PubMed ID: 16122284
[TBL] [Abstract][Full Text] [Related]
2. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
Bertilsson L
Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
5. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
[TBL] [Abstract][Full Text] [Related]
6. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
Christensen M; Tybring G; Mihara K; Yasui-Furokori N; Carrillo JA; Ramos SI; Andersson K; Dahl ML; Bertilsson L
Clin Pharmacol Ther; 2002 Mar; 71(3):141-52. PubMed ID: 11907488
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test.
Eap CB; Bondolfi G; Zullino D; Bryois C; Fuciec M; Savary L; Jonzier-Perey M; Baumann P
Ther Drug Monit; 2001 Jun; 23(3):228-31. PubMed ID: 11360030
[TBL] [Abstract][Full Text] [Related]
8. Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial.
Krösser S; Neugebauer R; Dolgos H; Fluck M; Rost KL; Kovar A
Eur J Clin Pharmacol; 2006 Apr; 62(4):277-84. PubMed ID: 16525816
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of antidepressants: clinical aspects.
Bertilsson L; Dahl ML; Tybring G
Acta Psychiatr Scand Suppl; 1997; 391():14-21. PubMed ID: 9265947
[TBL] [Abstract][Full Text] [Related]
10. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
Nielsen KK; Brøsen K; Hansen MG; Gram LF
Clin Pharmacol Ther; 1994 May; 55(5):518-27. PubMed ID: 8181196
[TBL] [Abstract][Full Text] [Related]
11. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study.
Gram LF; Guentert TW; Grange S; Vistisen K; Brøsen K
Clin Pharmacol Ther; 1995 Jun; 57(6):670-7. PubMed ID: 7781267
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of the cytochrome P450 2C19 genetic polymorphism.
Desta Z; Zhao X; Shin JG; Flockhart DA
Clin Pharmacokinet; 2002; 41(12):913-58. PubMed ID: 12222994
[TBL] [Abstract][Full Text] [Related]
13. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
Madsen H; Nielsen KK; Brøsen K
Br J Clin Pharmacol; 1995 Apr; 39(4):433-9. PubMed ID: 7640151
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.
Caccia S
Clin Pharmacokinet; 1998 Apr; 34(4):281-302. PubMed ID: 9571301
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacokinetics and drug interactions of antidepressive agents].
Sawada Y; Ohtani H
Nihon Rinsho; 2001 Aug; 59(8):1539-45. PubMed ID: 11519155
[TBL] [Abstract][Full Text] [Related]
16. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1.
Kharasch ED; Hankins DC; Jubert C; Thummel KE; Taraday JK
Drug Metab Dispos; 1999 Jun; 27(6):717-23. PubMed ID: 10348802
[TBL] [Abstract][Full Text] [Related]
17. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
Flaherty KT; Lathia C; Frye RF; Schuchter L; Redlinger M; Rosen M; O'Dwyer PJ
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1111-8. PubMed ID: 21350850
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype.
Al-Shurbaji A; Säwe J
Eur J Clin Pharmacol; 2002 Feb; 57(12):877-81. PubMed ID: 11936707
[TBL] [Abstract][Full Text] [Related]
19. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
20. Clinical importance of non-genetic and genetic cytochrome P450 function tests in liver disease.
Tanaka E
J Clin Pharm Ther; 1998 Jun; 23(3):161-70. PubMed ID: 9831966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
